Placement of Aortic Transcatheter Valves (Cohort A): TAVR vs. Surgical AVR | Clinical Trial - PARTNER Cohort A: TAVR vs. Surgical AVR
As many as one-third of patients with severe aortic stenosis (AS) are high-risk surgical candidates and are conservatively managed. However, nonsurgical management of symptomatic AS is associated with a median survival of about 2 years. The results of the PARTNER trial (cohort B) comparing medical therapy to transfemoral transcatheter aortic valve replacement (TAVR) in inoperable patients demonstrated a significant mortality benefit with TAVR over medical therapy.
The current trial (...